Meng-yuan Dai

Wuhan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.

Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.

Journal: Cell death & disease

Published: November 18, 2024

Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy.

Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy.

Journal: Journal of hematology & oncology

Published: July 19, 2024

Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.

Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.

Journal: Cell death & disease

Published: June 22, 2024

Targeting transcription factors through an IMiD independent zinc finger domain.

Targeting transcription factors through an IMiD independent zinc finger domain.

Journal: EMBO molecular medicine

Published: January 07, 2024

A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.

A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.

Journal: Frontiers in immunology

Published: June 10, 2023

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells.

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells.

Journal: Frontiers in immunology

Published: March 24, 2023

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.

Journal: Frontiers in pharmacology

Published: November 09, 2022

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.

Journal: Cell death & disease

Published: July 14, 2022

Patients With Lung Cancer Have High Susceptibility of COVID-19: A Retrospective Study in Wuhan, China.

Patients With Lung Cancer Have High Susceptibility of COVID-19: A Retrospective Study in Wuhan, China.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: September 17, 2020

Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.

Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.

Journal: Transfusion

Published: April 30, 2020

Phenethyl isothiocyanate induces apoptosis and inhibits cell proliferation and invasion in Hep-2 laryngeal cancer cells.

Phenethyl isothiocyanate induces apoptosis and inhibits cell proliferation and invasion in Hep-2 laryngeal cancer cells.

Journal: Oncology reports

Published: October 16, 2015

Downregulation of Notch1 induces apoptosis and inhibits cell proliferation and metastasis in laryngeal squamous cell carcinoma.

Downregulation of Notch1 induces apoptosis and inhibits cell proliferation and metastasis in laryngeal squamous cell carcinoma.

Journal: Oncology reports

Published: June 29, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026